Status:
ACTIVE_NOT_RECRUITING
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting
Eligibility Criteria
Inclusion
- Participants with prescriptions in deucravacitinib or any biologics as comparator group during the indexing period.
- Participants with at least one confirmed diagnosis of disease code for psoriasis within 12 months prior to the index date.
- Aged 18 years or older at the index date
Exclusion
- Participants with prescription in deucravacitinib or any biologics as comparator group prior to the index date.
- Participants with fewer than 12 months of available claim records prior to the index date.
- Participants with no claims record within 1-year after the index date (no visit after the index date).
- Specific for serious infection: Participants who had at least one disease code of hospitalized infection in the 60 days period before the index date.
- Specific for malignancy: Participants who had at least one disease code of malignancy prior to the index date
Key Trial Info
Start Date :
January 24 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2031
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06952465
Start Date
January 24 2025
End Date
November 30 2031
Last Update
May 1 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Tokyo, Japan, 171-0021
2
Medical Data Vision, Inc
Tokyo, Japan